Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study
Background: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number of metastatic sites (MS) remains unclear in patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess the prognostic impact of LM and MS n...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/1/83 |
| _version_ | 1797445707112644608 |
|---|---|
| author | Madeleine Maugeais Julien Péron Stéphane Dalle Amélie Boespflug Michaël Duruissaux Pauline Corbaux Thibault Reverdy Gulsum Sahin Aurélie Rabier Jonathan Lopez Nathalie Freymond Denis Maillet |
| author_facet | Madeleine Maugeais Julien Péron Stéphane Dalle Amélie Boespflug Michaël Duruissaux Pauline Corbaux Thibault Reverdy Gulsum Sahin Aurélie Rabier Jonathan Lopez Nathalie Freymond Denis Maillet |
| author_sort | Madeleine Maugeais |
| collection | DOAJ |
| description | Background: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number of metastatic sites (MS) remains unclear in patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess the prognostic impact of LM and MS number on progression-free survival (PFS) and overall survival (OS) in a large single-arm retrospective multicentric cohort (IMMUCARE) of patients treated with anti-PD(L)-1 for different solid tumors. Results: A total of 759 patients were enrolled from January 2012 to October 2018. The primary tumor types were non-small cell lung cancer (71%), melanoma (19%), or urologic cancer (10%). At the time of ICI initiation, 167 patients (22%) had LM and 370 patients (49%) had more than MS. LM was associated with a shorter median PFS of 1.9 months (95% CI: 1.8–2.5) vs. 4.0 months (95% CI: 3.6–5.4) in patients without LM (<i>p</i> < 0.001). The median OS of patients with LM was of 5.2 months (95% CI: 4.0–7.7) compared with 12.8 months (95% CI: 11.2–15.1) (<i>p</i> < 0.001). Interestingly, LM were not associated with shorter PFS, or OS compared to other MS types (brain, bone, or lung) in patients with only one MS. Patients with multiple MS also had poor clinical outcomes compared to patients with only one MS. The presence of LM and MS number were independent prognostic factors on overall survival. Conclusion: The presence of LM or multiple MS were associated with poorer survival outcomes in patients treated with anti-PD(L)-1. |
| first_indexed | 2024-03-09T13:30:41Z |
| format | Article |
| id | doaj.art-e7cc979200244e72838dc3ed0a64b7ec |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T13:30:41Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-e7cc979200244e72838dc3ed0a64b7ec2023-11-30T21:19:12ZengMDPI AGBiomedicines2227-90592022-12-011118310.3390/biomedicines11010083Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective StudyMadeleine Maugeais0Julien Péron1Stéphane Dalle2Amélie Boespflug3Michaël Duruissaux4Pauline Corbaux5Thibault Reverdy6Gulsum Sahin7Aurélie Rabier8Jonathan Lopez9Nathalie Freymond10Denis Maillet11Oncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, FranceOncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, FranceUniversité Claude Bernard Lyon 1, 69100 Villeurbanne, FranceUniversité Claude Bernard Lyon 1, 69100 Villeurbanne, FranceUniversité Claude Bernard Lyon 1, 69100 Villeurbanne, FranceOncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, FranceOncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, FranceOncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, FranceOncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, FranceUniversité Claude Bernard Lyon 1, 69100 Villeurbanne, FranceImmuCare (Immunology Cancer Research), Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69229 Lyon, FranceOncology Department, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), 69495 Pierre-Bénite, FranceBackground: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number of metastatic sites (MS) remains unclear in patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess the prognostic impact of LM and MS number on progression-free survival (PFS) and overall survival (OS) in a large single-arm retrospective multicentric cohort (IMMUCARE) of patients treated with anti-PD(L)-1 for different solid tumors. Results: A total of 759 patients were enrolled from January 2012 to October 2018. The primary tumor types were non-small cell lung cancer (71%), melanoma (19%), or urologic cancer (10%). At the time of ICI initiation, 167 patients (22%) had LM and 370 patients (49%) had more than MS. LM was associated with a shorter median PFS of 1.9 months (95% CI: 1.8–2.5) vs. 4.0 months (95% CI: 3.6–5.4) in patients without LM (<i>p</i> < 0.001). The median OS of patients with LM was of 5.2 months (95% CI: 4.0–7.7) compared with 12.8 months (95% CI: 11.2–15.1) (<i>p</i> < 0.001). Interestingly, LM were not associated with shorter PFS, or OS compared to other MS types (brain, bone, or lung) in patients with only one MS. Patients with multiple MS also had poor clinical outcomes compared to patients with only one MS. The presence of LM and MS number were independent prognostic factors on overall survival. Conclusion: The presence of LM or multiple MS were associated with poorer survival outcomes in patients treated with anti-PD(L)-1.https://www.mdpi.com/2227-9059/11/1/83immune checkpoint inhibitorsPD1 inhibitorsPDL1 inhibitorsmetastatic sitesliver metastasesprognostic biomarkers |
| spellingShingle | Madeleine Maugeais Julien Péron Stéphane Dalle Amélie Boespflug Michaël Duruissaux Pauline Corbaux Thibault Reverdy Gulsum Sahin Aurélie Rabier Jonathan Lopez Nathalie Freymond Denis Maillet Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study Biomedicines immune checkpoint inhibitors PD1 inhibitors PDL1 inhibitors metastatic sites liver metastases prognostic biomarkers |
| title | Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study |
| title_full | Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study |
| title_fullStr | Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study |
| title_full_unstemmed | Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study |
| title_short | Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study |
| title_sort | impact of liver metastases and number of metastatic sites on immune checkpoint inhibitors efficacy in patients with different solid tumors a retrospective study |
| topic | immune checkpoint inhibitors PD1 inhibitors PDL1 inhibitors metastatic sites liver metastases prognostic biomarkers |
| url | https://www.mdpi.com/2227-9059/11/1/83 |
| work_keys_str_mv | AT madeleinemaugeais impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT julienperon impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT stephanedalle impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT amelieboespflug impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT michaelduruissaux impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT paulinecorbaux impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT thibaultreverdy impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT gulsumsahin impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT aurelierabier impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT jonathanlopez impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT nathaliefreymond impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy AT denismaillet impactoflivermetastasesandnumberofmetastaticsitesonimmunecheckpointinhibitorsefficacyinpatientswithdifferentsolidtumorsaretrospectivestudy |